ELI LILLY AND CO Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ELI LILLY AND CO, and what generic alternatives to ELI LILLY AND CO drugs are available?
ELI LILLY AND CO has seven approved drugs.
There are nineteen US patents protecting ELI LILLY AND CO drugs. There is one tentative approval on ELI LILLY AND CO drugs.
There are three hundred and eighty-two patent family members on ELI LILLY AND CO drugs in fifty-six countries and forty-four supplementary protection certificates in eighteen countries.
Summary for ELI LILLY AND CO
| International Patents: | 382 |
| US Patents: | 19 |
| Tradenames: | 10 |
| Ingredients: | 6 |
| NDAs: | 7 |
| Drug Master File Entries: | 37 |
| Patent Litigation for ELI LILLY AND CO: | See patent lawsuits for ELI LILLY AND CO |
| PTAB Cases with ELI LILLY AND CO as petitioner: | See PTAB cases with ELI LILLY AND CO as petitioner |
| PTAB Cases with ELI LILLY AND CO as patent owner: | See PTAB cases with ELI LILLY AND CO as patent owner |
Drugs and US Patents for ELI LILLY AND CO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly And Co | MOUNJARO (AUTOINJECTOR) | tirzepatide | SOLUTION;SUBCUTANEOUS | 215866-002 | May 13, 2022 | RX | Yes | Yes | 9,474,780 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
| Eli Lilly And Co | ZEPBOUND (AUTOINJECTOR) | tirzepatide | SOLUTION;SUBCUTANEOUS | 217806-003 | Nov 8, 2023 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | |||||
| Eli Lilly And Co | MOUNJARO (AUTOINJECTOR) | tirzepatide | SOLUTION;SUBCUTANEOUS | 215866-004 | May 13, 2022 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | |||||
| Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-002 | Jan 31, 2020 | RX | Yes | Yes | 12,071,423 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Eli Lilly And Co | AXIRON | testosterone | SOLUTION, METERED;TRANSDERMAL | 022504-001 | Nov 23, 2010 | DISCN | Yes | No | 8,419,307 | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ELI LILLY AND CO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Eli Lilly And Co | SARAFEM | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-008 | Jul 6, 2000 | 5,114,976*PED | ⤷ Subscribe |
| Eli Lilly And Co | PROZAC | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-001 | Dec 29, 1987 | 4,035,511 | ⤷ Subscribe |
| Eli Lilly And Co | PROZAC | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-003 | Jun 15, 1999 | 4,314,081*PED | ⤷ Subscribe |
| Eli Lilly And Co | AXIRON | testosterone | SOLUTION, METERED;TRANSDERMAL | 022504-001 | Nov 23, 2010 | 6,818,226 | ⤷ Subscribe |
| Eli Lilly And Co | PROZAC | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-001 | Dec 29, 1987 | 4,683,235 | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ELI LILLY AND CO drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Topical Solution | 30 mg/1.5 mL | ➤ Subscribe | 2013-01-29 |
International Patents for ELI LILLY AND CO Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 2694410 | ⤷ Subscribe |
| Eurasian Patent Organization | 201991112 | ⤷ Subscribe |
| Ecuador | SP11011157 | ⤷ Subscribe |
| El Salvador | 2010003662 | ⤷ Subscribe |
| Canada | 2747055 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for ELI LILLY AND CO Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2288610 | 33/2017 | Austria | ⤷ Subscribe | PRODUCT NAME: BARICITINIB UND PHARMAZEUTISCH ANNEHMBARE SALZE DAVON; REGISTRATION NO/DATE: EU/1/16/1170 (MITTEILUNG) 20170215 |
| 3242887 | LUC00296 | Luxembourg | ⤷ Subscribe | PRODUCT NAME: TIRZEPATIDE ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/22/1685 20220919 |
| 2288610 | 17C0005 | France | ⤷ Subscribe | PRODUCT NAME: BARICITINIB; REGISTRATION NO/DATE: EU/1/16/1170 20170215 |
| 3242887 | C03242887/01 | Switzerland | ⤷ Subscribe | PRODUCT NAME: TIRZEPATID; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68726 02.11.2022 |
| 2379528 | 2019/015 | Ireland | ⤷ Subscribe | PRODUCT NAME: ABEMACICLIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/18/1307 20180927 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
